Oryn and University of Southern California Scientists Report Significant Advance in Antifungal Drug Therapy
November 26, 2019
Scientists from Oryn Therapeutics and University of Southern California have reported the successful application of Oryn’s novel therapeutic strategy to the treatment of multi-drug resistant fungal infections.
In a peer-reviewed paper published this month by Scientific Reports (https://www.nature.com/articles/s41598-019-53402-z ), the team describes the therapeutic efficacy of a cyclic host defense peptide drug candidate in treating invasive candidiasis, a fungal infection that is increasingly lethal. The data presented show that the drug candidate, which is both non-immunogenic and non-toxic to the host, is effective in curing systemic fungal infections and may be representative of the first new class of antifungal drugs to be introduced in over two decades. Based on these and other results, Oryn is pursuing the testing of newly-developed Orynotides for use against both fungal and bacterial pathogens as well as continuing its program to develop Orynotide-based treatment of chronic autoimmune diseases such as rheumatoid arthritis.